A NEW option offering **sustained symptom control** and the potential for **MORE GOOD DAYS.**

EXPERIENCE

The DAXXIFY® Difference

NAVIGATING CERVICAL DYSTONIA:

CLINICAL APPROACHES AND ACCESS CONSIDERATIONS

DAXXIFY®

daxibotulinumtoxinA-lanm injection

INDICATION

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT

The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

Please see Important Safety Information, including BOXED WARNING, throughout and see DAXXIFY® full Prescribing Information.

Sustained symptom control and the potential for MORE GOOD DAYS

DAXXIFY® significantly reduced pain, severity, and disability in the ASPEN-1 Phase 3 clinical trial as shown by the reduction of TWSTRS[1]

- ASPEN-1, a randomized, double-blind, placebo-controlled, multicenter clinical trial met the primary endpoint, demonstrating DAXXIFY® as efficacious at both 125U (n=125) and 250U (n=130)[1]

DAXXIFY® provides sustained symptom control for your patients[2-4]

In ASPEN-1, patients receiving DAXXIFY®:

Symptom re-emergence is common

The majority (up to 66%) of cervical dystonia patients suffer re-emergence of symptoms within <3 months following BoNT treatments[5]

BoNT, botulinum toxin; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale.

IMPORTANT SAFETY INFORMATION
Contraindications
DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Please see Important Safety Information, including BOXED WARNING, throughout and see DAXXIFY® full Prescribing Information.

DAXXIFY®
daxibotulinumtoxinA-lanm injection

Tailored treatment to meet your patient´s needs

DAXXIFY® allows you to customize treatment intervals for individual patient needs[6]



Patients that **requested re-treatment in ASPEN OLS**

still had

~50%

efficacy remaining[7]

Results from a 52-week, open-label, repeat-dose safety study (OLS) in which patients (n=357) received up to 4 treatments with DAXXIFY®. Patients initially received either 125U (n=111) or 250U (n=246) based on prior clinical experience with a BoNT and investigator clinical judgment. DAXXIFY® dose could be titrated in 50U-75U increments over successive treatments based on individual response. TWSTRS total score averaged over weeks 4 and 6.[1]

OLS, open-label, repeat-dose safety study.

IMPORTANT SAFETY INFORMATION (continued)
Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency units of DAXXIFY® are not interchangeable with preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Please see Important Safety Information, including BOXED WARNING, throughout and see DAXXIFY® full Prescribing Information.

DAXXIFY®
daxibotulinumtoxinA-lanm injection

Excellent safety profile

Rates of adverse events were low[1]

In the ASPEN-1 pivotal trial, most treatment-related adverse events were mild or moderate, with no serious treatment-related events.[1,9]

MUSCLE WEAKNESS	DYSPHAGIA	OTHER ADVERSE EVENTS	
		125U	**250U**
5% (125U) 2% (250U)	2% (125U) 4% (250U)	9% Headache 8% Injection site pain 5% Injection site erythema 2% Upper respiratory tract infection	7% Headache 5% Injection site pain 2% Injection site erythema 5% Upper respiratory tract infection

Rates of adverse events remained low with repeat treatments as dose titrated in ASPEN OLS[8]

ADVERSE EVENTS	*ASPEN OLS*			
	Cycle 1 (n=357)	Cycle 2 (n=329)	Cycle 3 (n=234)	Cycle 4 (n=65)
Muscular weakness	16 (5%)	17 (5%)	15 (6%)	2 (3%)
Dysphagia	15 (4%)	14 (4%)	12 (5%)	2 (3%)
Headache	11 (3%)	9 (3%)	3 (1%)	1 (2%)
Injection site pain	19 (5%)	9 (3%)	5 (2%)	2 (3%)
Injection site erythema	9 (3%)	6 (2%)	7 (3%)	1 (2%)
Arthralgia	4 (1%)	1 (0.3%)	0	2 (3%)

DAXXIFY® dose could be titrated in 50U-75U increments over successive treatments based on individual response.

IMPORTANT SAFETY INFORMATION (continued)
Adverse Reactions
The most commonly observed adverse reactions (≥5%) were headache (9%), injection site pain (8%), injection site erythema (5%), muscular weakness (5%), and upper respiratory tract infection (5%).

Please see Important Safety Information, including BOXED WARNING, throughout and see DAXXIFY® full Prescribing Information.

Experience extensive national coverage with DAXXIFY®

DAXXIFY®
daxibotulinumtoxinA-lanm injection

DAXXIFY® is covered for more than 150 million commercially insured and 50 million Medicare patients in the United States. [10]*



Since launch, **DAXXIFY® has widespread coverage.**

DAXXIFY® is covered for:



of your patients with commercial insurance.[10]*†

of your patients with Medicare.[10]*†

DAXXIFY® has a permanent J-Code!

J-CODE	10 DIGIT NDC	11 DIGIT NDC	BILLING UNITS
J0589	72960-112-01	72960-0112-01	100 units

Please visit hcp.daxxifycervicaldystonia.com/access-daxxify **OR** scan the QR code for more information on Access DAXXIFY™

*As of July 1, 2024. © 1998-2024 Managed Markets Insight & Technology, LLC. All rights reserved.
†Plans may require prior authorization for coverage of DAXXIFY®.

The information contained in this document is intended for informational purposes only and does not represent legal or billing advice. It is the responsibility of the provider and practice to ensure the accuracy of all information and claims that are submitted for reimbursement. This information is current as of July 2024 and may be subject to change. Revance makes no guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for any particular use given the frequent changes in public and private payer billing. The use of this information does not guarantee reimbursement.

NDC, National Drug Code.

IMPORTANT SAFETY INFORMATION (continued)
Drug Interactions
Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Please see Important Safety Information, including BOXED WARNING, throughout and see DAXXIFY® full Prescribing Information.

access DAXXIFY™

DAXXIFY®
daxibotulinumtoxinA-lanm injection

The Access DAXXIFY™ difference

Each member of our Revance team is dedicated to providing solutions tailored to your practice's needs with:

High-touch reimbursement managers

- Specialized, expert level of service for practices; support in navigating payer policies and requirements, billing, coding, and reimbursement

Traditional support services

- Benefits verification, prior authorization, and appeals support

Technology-enhanced support services

- Leverages technology for integrated benefits verification and prior authorization efficiencies

Best-in-class patient affordability programs

- Affordability programs to ensure patients have access to DAXXIFY®

Comprehensive practice support

- Practice-specific DAXXIFY® education; maximizing resources to support access to therapy

REFERENCES

1. DAXXIFY® Prescribing Information. Revance Therapeutics, Inc, 2023. **2.** Comella C, Jankovic J, Hauser R, et al. Efficacy and safety of DaxibotulinumtoxinA for Injection in cervical dystonia: ASPEN-1 phase 3 randomized controlled trial. *Neurology*. 2024;27:102(4)e208091. **3.** Data on File. TWSTRS total score, Kaplan-Meier analysis. Newark, CA: Revance Therapeutics, Inc, 2022. **4.** Data on File. Change from baseline in TWSTRS total score over time. Newark, CA: Revance Therapeutics, Inc, 2023. **5.** Comella C, Ferreira JJ, Pain E, Azoulai M, Om S. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. *J Neurol*. 2021;268(3):903-912. **6.** Data on File. Time to retreatment. Newark, CA: Revance Therapeutics, Inc, 2024. **7.** Ellenbogen A, Hauser RA, Patel A, et al. Efficacy remaining at time of requested retreatment following botulinum toxin treatment for cervical dystonia: potential for a new treatment paradigm with daxibotulinumtoxinA. Poster presented at: American Academy of Neurology Annual Meeting; April 13-18, 2024; Denver, CO. P1.015. **8.** Data on File. ASPEN OLS CSR. Newark, CA: Revance Therapeutics, Inc, 2022. **9.** Data on File. ASPEN-1 CSR. Newark, CA: Revance Therapeutics, Inc, 2021. **10.** Data on File. MMIT data. Newark, CA: Revance Therapeutics, Inc, 2024.

IMPORTANT SAFETY INFORMATION (continued)
Use in Specific Populations
DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including BOXED WARNING.

To report side effects associated with DAXXIFY®, please visit safety.revance.com or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

DAXXIFY® daxibotulinumtoxinA-lanm injection | REVANCE® THERAPEUTICS